WADA S2
This substance falls under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). If you are subject to anti-doping rules, this category of substances is prohibited at all times.
Evidence visual
AOD-9604 evidence and risk matrix
intermediate researcher fit
Evidence
Tier B
Risk
med high
Regulatory
not approved
WADA
S2
FDA
unknown
Route
oral
Higher-confidence evidence profile, but regulatory and sourcing checks still matter.
Overview
AOD-9604 is proposed to capture the lipolytic signaling of GH without full GH receptor effects. Mouse studies describe interaction with β-adrenergic pathways (β3-AR) and increased lipolytic sensitivity. Human obesity trials include daily oral dosing across 1-30 mg/day ranges in 12-week designs. Weight loss signals were modest. WADA lists AOD-9604 and hGH fragments as GH fragments under S2.
Decision path
Where AOD-9604 fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether AOD-9604 belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
Proposed lipolytic signaling of GH without full GH receptor effects; β3-AR pathway interaction described in mice.
oral, subcutaneous
Human obesity trials: oral 1-30 mg/day for 12 weeks.
Modest lipolytic/fat loss signals in trials. Not equivalent to GLP-1 class.
Clinical trials measured outcomes over ~12 weeks; weight loss signals modest.
No formal label.
Overall tolerability similar to placebo in safety reports; some serious AEs in dose groups (judged unrelated by investigators).
Minimal established interactions.
Cost at a glance
Typical cycle cost
€963.31
Estimated monthly
€321.10
Protocol style
12-24 week phase
Phase-based
Estimate confidence
High confidence
Assumes roughly 84 mg–168 mg per cycle, using 1 tracked affiliated listing.
Reflects fat-loss style use over a longer multi-month block rather than a single month.
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for AOD-9604.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.